MARKET

PCSA

PCSA

Processa Pharmaceuticals Inc
NASDAQ
2.380
+0.210
+9.68%
Pre Market: 2.450 +0.07 +2.94% 04:02 02/09 EST
OPEN
2.140
PREV CLOSE
2.170
HIGH
2.450
LOW
2.100
VOLUME
15
TURNOVER
0
52 WEEK HIGH
19.63
52 WEEK LOW
2.050
MARKET CAP
5.39M
P/E (TTM)
-0.0680
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 2d ago
Weekly Report: what happened at PCSA last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at PCSA last week (0119-0123)?
Weekly Report · 01/26 09:50
Weekly Report: what happened at PCSA last week (0112-0116)?
Weekly Report · 01/19 09:54
Processa Pharmaceuticals to Present Clinical Pipeline at J.P. Morgan Healthcare Conference
Reuters · 01/12 14:15
Weekly Report: what happened at PCSA last week (0105-0109)?
Weekly Report · 01/12 09:52
Processa Pharmaceuticals Regains Nasdaq Minimum Bid Compliance
TipRanks · 01/07 13:58
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 01/07 12:05
More
About PCSA
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.

Webull offers Processa Pharmaceuticals Inc stock information, including NASDAQ: PCSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCSA stock methods without spending real money on the virtual paper trading platform.